Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for triglyceride deposit cardiomyovasculopathy has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
10 publications have been identified in PubMed for triglyceride deposit cardiomyovasculopathy. Research spans Case Report / Case Series (30%), Epidemiology / Natural History (20%), and Other (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 3 | 30% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression |
2 |
20% |
Other research | 1 | 10% |
Testing and diagnosis research | 1 | 10% |
Research summaries | 1 | 10% |
Clinical study results | 1 | 10% |
Laboratory research | 1 | 10% |
Fujimoto M (2026). [PMID: 42015807](https://pubmed.ncbi.nlm.nih.gov/42015807/). *Ren Fail*. [Epidemiology / Natural History]
Mori T (2026). [PMID: 41980667](https://pubmed.ncbi.nlm.nih.gov/41980667/). *J Cardiol*. [Review / Meta-Analysis]
Hirano KI (2025). [PMID: 41368557](https://pubmed.ncbi.nlm.nih.gov/41368557/). *Ann Nucl Cardiol*. [Other]
Nakano T (2025). [PMID: 41137191](https://pubmed.ncbi.nlm.nih.gov/41137191/). *J Investig Med*. [Diagnostic / Biomarker]
Ono R (2025). [PMID: 41368555](https://pubmed.ncbi.nlm.nih.gov/41368555/). *Ann Nucl Cardiol*. [Basic Science / Preclinical]
Nagasawa Y (2025). [PMID: 39809936](https://pubmed.ncbi.nlm.nih.gov/39809936/). *Clin Exp Nephrol*. [Epidemiology / Natural History]
Chishaki S (2025). [PMID: 41550214](https://pubmed.ncbi.nlm.nih.gov/41550214/). *HeartRhythm Case Rep*. [Case Report / Case Series]
Hirano KI (2025). [PMID: 39948308](https://pubmed.ncbi.nlm.nih.gov/39948308/). *Nat Cardiovasc Res*. [Clinical Trial Publication]
Wang S (2024). [PMID: 39119584](https://pubmed.ncbi.nlm.nih.gov/39119584/). *Front Genet*. [Case Report / Case Series]
Yamamoto H (2024). [PMID: 39525815](https://pubmed.ncbi.nlm.nih.gov/39525815/). *CJC Open*. [Case Report / Case Series]
AI-curated news mentioning triglyceride deposit cardiomyovasculopathy
Updated Aug 4, 2026
A new study highlights the paradoxical native T1 elevation in triglyceride deposit cardiomyovasculopathy, which may lead to misdiagnosis when compared to Fabry disease. This research underscores the need for careful differentiation between these two conditions in clinical settings.